AP Biosciences

AP Biosciences Current Liabilities

The Current Liabilities of AP Biosciences (6945.TWO) as of Nov 17, 2026 is 288,000.00 TWD. In the previous year, Current Liabilities was 55.65 M TWD — a change of -99.48% (lower).

Current Liabilities

288,000.00TWD

YoY

-99.48%

Last updated:

Current Liabilities of AP Biosciences is 2025 288,000.00 TWD. Current Liabilities of AP Biosciences was 2024 55.65 M TWD. It decreases by -99.48% lower compared to the previous year.

The AP Biosciences Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2020
1.79 M TWD
Jan 1, 2021
23.41 M TWD
Jan 1, 2022
6.42 M TWD
Jan 1, 2023
45.72 M TWD
Jan 1, 2024
55.65 M TWD
Jan 1, 2025
288,000.00 TWD
The AP Biosciences Current Liabilities history
YEARCurrent LiabilitiesYoY
288,000.00TWD-99.48%
55.65 MTWD+21.72%
45.72 MTWD+612.56%
6.42 MTWD-72.60%
23.41 MTWD+1,208.66%
1.79 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AP Biosciences Stock analysis

What does AP Biosciences do? AP Biosciences Inc generates revenue through the development and commercialization of protein and antibody drugs. The company focuses on early-stage drug candidates and preclinical trials, utilizing its technology platforms to create monoclonal and bispecific antibody drugs. Key products include IBI302, OmniMab, AP505, T-cube, and AP203, which target specific disease mechanisms and therapeutic areas. The primary buyers are pharmaceutical companies seeking to expand their drug pipelines through partnerships and licensing agreements. The firm's technology platforms, such as OmniMab fully human antibody library and T-cube, enable the development of novel bispecific antibodies. These platforms support the creation of drugs like AP505-PD-L1 x VEGF bispecific antibody and AP203-PD-L1 x CD137 fully human bispecific antibody, which are designed for specific therapeutic targets. The company's research and development efforts target diseases with high unmet medical needs, attracting interest from potential collaborators in the biopharmaceutical sector. AP Biosciences Inc's business model relies on advancing its pipeline of drug candidates through preclinical and clinical stages, with the goal of securing partnerships or licensing deals with larger pharmaceutical firms. The company's focus on bispecific antibody technology and its proprietary platforms positions it to generate revenue from milestone payments and royalties upon successful development and commercialization of its drug candidates. AP Biosciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AP Biosciences stock

Current Liabilities of AP Biosciences is 288,000.00 TWD in 2025.

Current Liabilities of AP Biosciences changed from 55.65 M TWD to 288,000.00 TWD, representing a -99.48% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities AP Biosciences since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's AP Biosciences historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AP Biosciences

All Key Metrics — AP Biosciences